GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
GE HealthCare launched Flyrcado™ (flurpiridaz F 18) at the recent American College of Cardiology (ACC) conference. A positron emission tomography myocardial perfusion imaging (PET MPI) agent for coronary artery disease (CAD) detection, Flyrcado offers ready to use unit dosing and a half-life that is reportedly 10 times higher than that of other cardiac positron emission tomography (PET) agents.
In research presented at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, Flyrcado demonstrated higher sensitivity and specificity rates than single photon emission computed tomography (SPECT) imaging for the detection of CAD in patients with high body mass index (BMI).
Offering ready to use unit dosing and a half-life that is reportedly 10 times higher than that of other cardiac positron emission tomography (PET) agents, the positron emission tomography myocardial perfusion imaging (PET MPI) agent Flyrcado™ will be launched at the American College of Cardiology (ACC) conference. (Image courtesy of GE HealthCare.)
Approved by the FDA in 2024, Flyrcado may facilitate enhanced assessment of ischemia through a combination of exercise stress testing and cardiac PET imaging, according to GE HealthCare, the manufacturer of Flyrcado.
“The launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected coronary artery disease,” said Eric Ruedinger, the vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics segment for the U.S. and Canada.
The company added that Flyrcado recently garnered pass-through payment status from the Centers for Medicare and Medicaid Services (CMS). GE HealthCare said the pass-through payment status, which goes into effect on April 1, 2025, allows separate reimbursement for the radiopharmaceutical and the PET imaging.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
